Cargando…

Single exposure of dopamine D1 antagonist prevents and D2 antagonist attenuates methylphenidate effect

Methylphenidate (MPD) is a readily prescribed drug for the treatment of attention deficit hyperactivity disorder (ADHD) and moreover is used illicitly by youths for its cognitive-enhancing effects and recreation. MPD exposure in rodents elicits increased locomotor activity. Repetitive MPD exposure l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Claussen, Catherine M, Witte, Lindsey J, Dafny, Nachum
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863529/ https://www.ncbi.nlm.nih.gov/pubmed/27186140 http://dx.doi.org/10.2147/JEP.S75300

Ejemplares similares

Acute administration of methylphenidate alters the prefrontal cortex neuronal activity in a dose–response characteristic
por: Claussen, Catherine M, et al.
Publicado: (2014)

Dose-response characteristics of methylphenidate on locomotor behavior and on sensory evoked potentials recorded from the VTA, NAc, and PFC in freely behaving rats
por: Yang, Pamela B, et al.
Publicado: (2006)

The Universal 3D QSAR Model for Dopamine D(2) Receptor Antagonists
por: Zięba, Agata, et al.
Publicado: (2019)

Structure-based development of caged dopamine D(2)/D(3) receptor antagonists
por: Gienger, Marie, et al.
Publicado: (2020)

Effects of dopamine D(4 )receptor antagonist on spontaneous alternation in rats
por: Moustgaard, Anette, et al.
Publicado: (2008)

Examining the Effects of Sodium Ions on the Binding of Antagonists to Dopamine D(2) and D(3) Receptors
por: Newton, Claire L., et al.
Publicado: (2016)

Distinct Dopamine D(2) Receptor Antagonists Differentially Impact D(2) Receptor Oligomerization
por: Wouters, Elise, et al.
Publicado: (2019)

Discovery, Optimization, and Characterization of Novel D(2) Dopamine Receptor Selective Antagonists
por: Xiao, Jingbo, et al.
Publicado: (2014)

Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases
por: Maramai, Samuele, et al.
Publicado: (2016)

Effect of Dopamine D(2) Receptor Antagonists on [(18)F]-FEOBV Binding
por: Schildt, Anna, et al.
Publicado: (2020)

Association of dopamine-related genetic loci to dopamine D3 receptor antagonist ABT-925 clinical response
por: Bhathena, A, et al.
Publicado: (2013)

Effect of D1- and D2-like Dopamine Receptor Antagonists on the Rewarding and Anxiolytic Effects of Neurotensin in the Ventral Pallidum
por: Ollmann, Tamás, et al.
Publicado: (2022)

Tranylcypromine Substituted cis-Hydroxycyclobutylnaphthamides as Potent and Selective Dopamine D(3) Receptor Antagonists
por: Chen, Jianyong, et al.
Publicado: (2014)

Dopamine D3 receptor antagonist reveals a cryptic pocket in aminergic GPCRs
por: Ferruz, Noelia, et al.
Publicado: (2018)

High Affinity Dopamine D(3) Receptor (D(3)R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D(3)R Knockout Mice
por: Boateng, Comfort A., et al.
Publicado: (2015)

In Vitro and In Silico Characterization of Kurarinone as a Dopamine D(1A) Receptor Antagonist and D(2L) and D(4) Receptor Agonist
por: Prajapati, Ritu, et al.
Publicado: (2021)

A Molecular Basis for Selective Antagonist Destabilization of Dopamine D(3) Receptor Quaternary Organization
por: Marsango, Sara, et al.
Publicado: (2017)

Highly Potent and Selective Dopamine D(4) Receptor Antagonists Potentially Useful for the Treatment of Glioblastoma
por: Pavletić, Pegi, et al.
Publicado: (2022)

Striatal TRPV1 activation by acetaminophen ameliorates dopamine D(2) receptor antagonist–induced orofacial dyskinesia
por: Nagaoka, Koki, et al.
Publicado: (2021)

Immunotherapy as a treatment to confront the ongoing opioid epidemic- A review
por: Dafny, Nachum
Publicado: (2022)

In vitro and in silico analysis of the effects of D (2) receptor antagonist target binding kinetics on the cellular response to fluctuating dopamine concentrations
por: de Witte, Wilhelmus E A, et al.
Publicado: (2018)

Author Correction: Dopamine D3 receptor antagonist reveals a cryptic pocket in aminergic GPCRs
por: Ferruz, Noelia, et al.
Publicado: (2019)

Development and Characterization of Novel Selective, Non-Basic Dopamine D(2) Receptor Antagonists for the Treatment of Schizophrenia
por: Stępnicki, Piotr, et al.
Publicado: (2023)

Carbazole and tetrahydro-carboline derivatives as dopamine D(3) receptor antagonists with the multiple antipsychotic-like properties
por: Li, Zhongtang, et al.
Publicado: (2023)

Prenatal Exposure to Methylphenidate Affects the Dopamine System and the Reactivity to Natural Reward in Adulthood in Rats
por: Lepelletier, François-Xavier, et al.
Publicado: (2015)

Cortical D1 and D2 dopamine receptor availability modulate methylphenidate-induced changes in brain activity and functional connectivity
por: Manza, Peter, et al.
Publicado: (2022)

Accelerated habit formation following amphetamine exposure is reversed by D(1), but enhanced by D(2), receptor antagonists
por: Nelson, Andrew J. D., et al.
Publicado: (2013)

Roles of dopamine receptors and their antagonist thioridazine in hepatoma metastasis
por: Lu, Meiling, et al.
Publicado: (2015)

Dopamine receptor antagonists as potential therapeutic agents for ADPKD
por: Paul, Parama, et al.
Publicado: (2019)

M198. INVESTIGATIONAL DOPAMINE ANTAGONISTS FOR THE TREATMENT OF SCHIZOPHRENIA
Publicado: (2020)

Abnormal modulation of reward versus punishment learning by a dopamine D2-receptor antagonist in pathological gamblers
por: Janssen, Lieneke Katharina, et al.
Publicado: (2015)

Cocaine-Induced Behavioral Sensitization in Mice: Effects of Microinjection of Dopamine D2 Receptor Antagonist into the Nucleus Accumbens
por: Jung, Eun-Sol, et al.
Publicado: (2013)

The dopamine D(2) receptor dimer and its interaction with homobivalent antagonists: homology modeling, docking and molecular dynamics
por: Kaczor, Agnieszka A., et al.
Publicado: (2016)

Modeling of prolactin response following dopamine D(2) receptor antagonists in rats: can it be translated to clinical dosing?
por: Taneja, Amit, et al.
Publicado: (2017)

A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer
por: Paraghamian, Sarah E., et al.
Publicado: (2023)

Structure–Activity Relationship Studies on 6-Chloro-1-phenylbenzazepines Leads to the Identification of a New Dopamine D1 Receptor Antagonist
por: Giri, Rajan, et al.
Publicado: (2023)

Dopamine D(2)-Receptor Antagonists Down-Regulate CYP1A1/2 and CYP1B1 in the Rat Liver
por: Harkitis, P., et al.
Publicado: (2015)

The effect of a dopamine antagonist on conditioning of sexual arousal in women
por: Brom, Mirte, et al.
Publicado: (2016)

Methylphenidate Exposure Induces Dopamine Neuron Loss and Activation of Microglia in the Basal Ganglia of Mice
por: Sadasivan, Shankar, et al.
Publicado: (2012)

Studies of New Fused Benzazepine as Selective Dopamine D3 Receptor Antagonists Using 3D-QSAR, Molecular Docking and Molecular Dynamics
por: Liu, Jing, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_9i9h4cv22c62vcesd8d10ivaqj